Ivuxolimab

艾沃利单抗

Report date: 2024/01/15 10:55:44

Base Information

Drug NameIvuxolimab
Drug Alias NamePF-8600PF-04518600
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 agonists
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsBone metastasesSolid tumoursProstatic Neoplasms, Castration-Resistant +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesArray BiopharmaPfizer IncUniversity Of Southern California +[4] 
Inactive CompaniesN/A
Active IndicationsBone metastasesSolid tumoursProstatic Neoplasms, Castration-Resistant +[11] 
Inactive IndicationsLymphoma, FollicularNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A